Germany Issues Benefit Assessment For InterMune’s Esbriet, Despite Orphan Drug Status
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s senior health technology assessment body, the G-BA, has said that InterMune’s Esbriet is beneficial, but says it is unsure to what extent. However, such added value assessments for orphan drugs could be illegal.
You may also be interested in...
U.K.’s NICE Backs Esbriet, Xolair And Orencia After Getting Price Discounts
In a day of three positive recommendations helped by discounts, Bristol’s Orencia for rheumatoid arthritis, Novartis’ Xolair for Asthma and InterMune’s Esbriet for IPF finally make it onto the U.K.’s NHS payroll.
Vertex’s Kalydeco May Face Added Cost Assessments In Germany
Vertex Pharmaceutical’s orphan drug for cystic fibrosis may face an additional reimbursement evaluation in Germany after IQWiG says it may breach the €50 million per year cost threshold.
European HTA Highlights: Discounts Soften NICE Approach But Germany’s IQWiG Shows Its Teeth
It is becoming ever more clear that the overriding factor in NICE’s decision-making process is a desire to see cost-effectiveness, irrespective of the clinical benefit of a drug. But in Germany, companies are challenged by IQWiG’s tightened-up, science-based review system.